Modified Release Gamma-Hydroxybutyrate Formulation for Narcolepsy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current modified release formulations of sodium oxybate for narcolepsy often result in reduced bioavailability and require twice-nightly administration, which is inconvenient and can disrupt sleep.
Innovation Solution
A modified release formulation of gamma-hydroxybutyrate that rapidly releases half of its dose in 0.1N hydrochloric acid and the other half in phosphate buffer, allowing for once-nightly administration with improved bioavailability comparable to twice-nightly immediate release solutions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If a modified release formulation of sodium oxybate is used, then the convenience of administration is improved (once-nightly dosing), but the bioavailability is reduced compared to immediate release formulations
Solution Approach 1:
The formulation is divided into two distinct portions: an immediate release portion that rapidly releases gamma-hydroxybutyrate upon contact with gastric acid, and a modified release portion that provides sustained release in the intestinal tract. This segmentation allows the formulation to achieve both convenient once-nightly dosing and reliable bioavailability by ensuring rapid absorption in the stomach while providing extended release in the intestine.
Solution Approach 2:
The invention changes the release parameters of gamma-hydroxybutyrate by using different dissolution media with distinct pH characteristics (0.1N HCl for immediate release, phosphate buffer for modified release). This parameter change enables the formulation to achieve rapid initial release followed by sustained release, resolving the contradiction between administration convenience and bioavailability.
2Reliability
If immediate release liquid solution of sodium oxybate is administered twice nightly, then the bioavailability is maximized, but the treatment convenience deteriorates and sleep disruption occurs
Solution Approach 1:
The invention merges the characteristics of immediate release and modified release formulations into a single hybrid formulation. The immediate release portion provides rapid bioavailability similar to conventional liquid solutions, while the modified release portion enables once-nightly dosing. This merging eliminates the need for twice-nightly administration while maintaining reliable bioavailability.
3Reliability
If the dosage is increased to compensate for reduced bioavailability in modified release formulations, then the therapeutic effect is maintained, but the adverse reactions increase
Solution Approach 1:
The modified release portion ensures continuous release of gamma-hydroxybutyrate in the intestinal tract, maintaining therapeutic levels without requiring dose escalation. This continuous action provides sustained therapeutic effect while avoiding the peak concentrations that lead to adverse reactions, thus resolving the contradiction between maintaining efficacy and minimizing harm.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves a bioavailability comparable to twice-nightly immediate release solutions of sodium oxybate, providing effective treatment for narcolepsy with fewer adverse reactions and improved convenience.
Implementation Method 1
rapidly releases half of its dose in 0.1N hydrochloric acid and the other half in phosphate buffer
Data Source
AI summary
Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.